AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04765475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and COVID-19 Symptom Monitoring System
Description: A combination of: 1) a culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years); 2) a daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts
Study NCT04765475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Services
Description: Provision of supportive services such as referrals to needed medical, mental or behavioral health care and delivery of a hygiene kit containing basic hygiene supplies. Participants will also be provided information on COVID-19 and nearby testing locations and basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19.
Study NCT04765475 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supportive Services
Description: Provision of supportive services such as referrals to needed medical, mental or behavioral health care and delivery of a hygiene kit containing basic hygiene supplies. Participants will also be provided information on COVID-19 and nearby testing locations and basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19.
Study NCT05017753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracentesis
Description: Thoracentesis will be performed according to local practice, either at the ward or at the radiology department, in addition to standard-of-care medical treatment.
Study NCT05017753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care medical treatment
Description: Standard-of-care medical treatment
Study NCT06049082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB408 (Nebulization)
Description: Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
Study NCT05931003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid stenting
Description: In carotid stenting, a long, hollow tube (catheter) is threaded through the arteries to the narrowed carotid artery in the neck. A metal mesh tube (stent) is inserted into the vessel to serve as a scaffold that helps prevent the artery from narrowing again. The catheter and the filter - which catches any debris that may break off during the procedure - are removed.
Study NCT05931003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid endarterectomy
Description: Carotid endarterectomy is a procedure to treat carotid artery disease. In carotid endarterectomy receive general anesthesia. Surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging artery. Then, surgeon repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Sometimes surgeons may use another technique called eversion carotid endarterectomy. This involves cutting the carotid artery and turning it inside out, then removing the plaque. Surgeon then reattaches the artery.
Study NCT04897009 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood and tissue collection
Study NCT05933863 — intervention group
Intervention type: DRUG
Intervention: PD-(L)1 antibody immunotherapy
Description: The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.
Study NCT05603884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen
Description: venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles； 1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles；~1）dicitabine 25mg d1-3，2）liposome mitoxantrone 20mg d4，3）cytarabine 10mg/m2 Q12h d1-7 4）G-CSF 300ug d-1 until WBC > 20×109/L
Study NCT06378411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music Game Intervention
Description: Use of music to induce improvements in cognitive and motor outcomes.
Study NCT06378411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Music Game Intervention
Description: Use of music to induce improvements in cognitive and motor outcomes.
Study NCT05326113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: After POEM, patient underwent physiotherapy consisting of diaphragmatic breathing and dynamic stabilization exercises and PPIs
Study NCT05326113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: All patients will be treated with standard course of PPIs after POEM without physiotherapy.
Study NCT04633174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sous Vide Device (SVD)
Description: A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer every 2 minutes. At the end of the 30 minute treatment, the SVD will be powered off and the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
Study NCT05805566 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Blood samples will be collected from the patient at baseline. This blood will be collected during the standard of care blood drawing in extra.
Study NCT06314776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapy without Whole-Body Vibration
Description: Manual Therapy, passive and active mobilizations, stretching, respiratory techniques
Study NCT06314776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Usual physiotherapy
Description: (GMFM, Test 10M, Test Time Up and Go)
Study NCT06314776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-Usual physiotherapy
Description: (GMFM, Test 10M, Test Time Up and Go)
Study NCT06159855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group: nurse-led education for bowel preparation of colonoscopy
Description: 1. PRE-TEST~   a) Patients will be evaluated using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~2. INTERVENTION~   1. Patients will be given face-to-face training in the clinic training room of the unit.~  2. After face-to-face training is given, an educational brochure will be given to the patient.~  3. If the patient is constipated, the bowel preparation diet is requested to be started 5 days in advance. If the patient is not constipated, the bowel preparation diet is started 3 days in advance.~  4. After the intervention group is given bowel preparation training, reminders about colonoscopy will be made via instant messaging 3 to 5 days before the day of the colonoscopy.~3. LAST TEST~   1. Data will be collected again using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~  2. The cleanliness of the intestines will be evaluated by the physician using the Ottawa Bowel Preparation Scale.
Study NCT06227403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership, Engagement, and youth Activism Program with Mindfulness
Description: The Leadership, Engagement, and youth Activism Program with Mindfulness intervention (LEAP-M) was designed and co-created with youth to improve youth wellbeing by enhancing civic engagement and leadership opportunities and by developing mindfulness in day-to-day life. LEAP-M seeks to foster these improvements in youth of color as a strategy to combat structural racism encountered at school- and neighborhood-levels and to increase youth mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
Study NCT06227403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EnvisionIT
Description: Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential transition skills and digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
Study NCT06611111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone (Rocephin®)
Description: Slightly yellow liquid.
Study NCT06611111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% (D5W)
Description: Colorless liquid
Study NCT06616272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical rehabilitation
Description: * Manual joint mobilization (Grades I-V) of painful and restricted cervical spine segments.~* Supine manual cervical traction to stretch and mobilize the cervical spinal tissues.~* Manual soft tissue mobilization of the cervical, upper thoracic and/or shoulder muscles.~* Passive stretching of hypertonic muscles and active strengthening of hypotonic muscles.~* Motor-control and isometric exercises to activate the deep neck flexors.
Study NCT06616272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Concussion Care
Description: Standard Concussion Care interventions are individualized to each patient and their adjudicated profile(s)/moderating factor(s) and may include any/all of the following:~* Behavioral regulation~* Vestibular rehabilitation~* Oculomotor rehabilitation~* Exertion rehabilitation~* Pharmacological management~* Behavioral sleep intervention~* \*Cervical spine rehabilitation (the variable of interest in this study)~* Psychotherapy
Study NCT05120856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAT-App
Description: Participants will receive the active AAT-App on their smartphone, which includes ApBM training, and prompted to engage with the app during the 28-day intervention period.
Study NCT05120856 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Minimal AAT-App
Description: Participants will receive the minimal version of AAT-App, which does not include ApBM training, on their smartphone and prompted to engage with the app during the 28-day intervention period.
Study NCT06708520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rupatadine
Description: 10 mg tablets
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine intramuscular injection 20mg qd d0-2 Q3W
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab intravenous infusion 200mg d1
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab intravenous infusion 200mg d1
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed intravenous infusion 500mg/m2 d1
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed intravenous infusion 500mg/m2 d1
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: Albumin paclitaxel intravenous infusion 260mg/m2 d1
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin paclitaxel
Description: Albumin paclitaxel intravenous infusion 260mg/m2 d1
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion AUC5 d1
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin intravenous infusion AUC5 d1
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin intravenous infusion 75mg/m2 d1
Study NCT06704620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin intravenous infusion 75mg/m2 d1
Study NCT06723418 — intervention group
Intervention type: OTHER
Intervention: Malnutriton Screening Tool (PYMS)
Description: In a pilot implementation study, PYMS will be used on children with IBD attending the outpatient and inpatient hospital clinics
Study NCT06252519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAC
Description: 1 375 mg capsule containing N-acetyl cysteine
Study NCT06252519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neuro-NAC
Description: 3 capsules containing a total of 375 mg N-Acetyl L-Cysteine Ethyl Ester
Study NCT06252519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neuro-NAC XS
Description: 3 capsules containing a total of 75 mcg Selenium, 150 mcg Molybdenum, 1800 mg Glycine, and 375 mg N-Acetyl L-Cysteine Ethyl Ester
Study NCT06735092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise-Only Group (Control Group)
Description: Participants in this group will only undergo a standardized exercise protocol. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
Study NCT06735092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + Forearm Counterforce Brace Group
Description: Participants in this group will undergo a standardized exercise protocol and will be provided with a counterforce forearm brace in addition to exercise therapy. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
Study NCT06735092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + Wrist Brace Group
Description: Participants in this group will undergo a standardized exercise protocol and will be provided with a wrist brace in addition to exercise therapy. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
Study NCT06735677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual health education
Description: These sessions covered reproductive health, sexual activity during pregnancy and the postpartum period, personal and sexual hygiene, domestic violence during pregnancy, and misconceptions about pregnancy.
Study NCT06735066 — intervention group
Intervention type: PROCEDURE
Intervention: Ascending urethrocystography
Description: It will be performed after instructing the patient to evacuate the bladder. A contrast agent will be infused through the urethra under fluoroscopy, using a urethral catheter or Knutson's clamp at the external urethral meatus. When the bladder is full, an anteroposterior film and two oblique films will be taken. Voiding cystourethrography will be performed as a part of this imaging examination. From this procedure, the following findings may be diagnosed:~* Upper urinary tract: Vesicoureteral reflux (VUR); laterality and degrees of VUR will be defined.~* Bladder: Capacity (defunctionalized, Small-sized or contracted bladder), neurogenic bladder, bladder diverticulum, filling defects, etc.~* Urethra: Stricture and filling defects.
Study NCT06734299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen A
Description: Sunscreen A will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
Study NCT06734299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen B
Description: Sunscreen B will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
Study NCT06734299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen C
Description: Sunscreen C will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
Study NCT06734845 — intervention group
Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Total Joint (Knee or Hip) Arthroplasty
Study NCT06734845 — intervention group
Intervention type: PROCEDURE
Intervention: Total Joint Arthroplasty
Description: Participants will be patients undergoing first total knee or total hip replacement
Study NCT06734286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CogMed
Description: CogMed which is a computerized working memory training program developed by Karolinska University.
Study NCT06736080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MUNC-CD34
Description: * Dosage: ≥ 2 x10e6 CD34/kg after thawing, dose limit: 20x10e6 CD34+ cells/kg~* Route of administration: intravenous, on D0
Study NCT06736080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MUNC-T3
Description: * Dosage: \[1.10e4; 5.10e6\] T-CD3+/kg after thawing,~* Route of administration: intravenous, on D14 post-GT +/- D28 In case of persistent circulating T-cell after the HLH remission at inclusion, the MUNC-CD34 will be completed by MUNC-T3 infusion
Study NCT06734091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PrestoCHILL
Description: PrestoCHILL (Milestone Medical Technologies, Inc.MI 49009, USA)which by reducing the tissue freezing time to less than 60 seconds should eliminate freezing artefacts and improve the quality of sections for morphological and IHC examination. In selected cases and according to the diagnostic algorithm required for the diagnosis of specific neoplasms, rapid IHC analysis will be performed with the Benchmark ULTRA® immunostainer (Ventana Medical Systems), which is already in place to confirm or exclude the suspected neoplasm, as well as to confirm the histotype. For the latter purpose, commercially available antibody panels for routine examinations will be used (Ventana/Roche,Ventana Medical Systems, USA).
Study NCT06735053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality group
Description: Virtual reality group will perform online reality-based device following a therapeutic protocol supervised by a physiotherapist in which the level of demand will be adjusted to the patient's evolution. This programme provides a gamified and challenging online environment to enhance motor learning and induce sensorimotor adaptations. Additionally, they will receive conventional physiotherapy approach, oriented to the specific objectives of each patient, aiming to normalize tone, activate weakened muscles, facilitate movement, recover sensitivity, and compensate for functional deficits. Additionally, global kinesitherapy, motor coordination exercises, pedalier, vibration therapy (vibrosphere®), and analgesic electrotherapy will be performed if necessary.
Study NCT06735053 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo virtual reality group
Description: The control group will undergo a conventional physiotherapy program based on the normalization of tone, activation of weakened muscles and facilitation of normal movement, recovery of alterations in sensitivity, and compensation of lost functional deficits. In addition, global kinesitherapy exercises will be performed on a stretcher, motor coordination exercises, pedalier, vibration therapy (vibrosphere ®) and analgesic electrotherapy if necessary. Finally, in order to minimize the differences between the control and intervention groups, the participants of the control group will watch a 15-minute generic 2D video freely accessible on the Youtube platform from the VR glasses, without specific software.
Study NCT06444217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: skin biopsy
Study NCT05859750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 (6mg/kg) on day 1, IV, Q2W
Study NCT05859750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 (10mg/kg) on day 1, IV, Q2W